Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders... Show more
A.I.dvisor indicates that over the last year, RAPP has been loosely correlated with CGEM. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if RAPP jumps, then CGEM could also see price increases.
| Ticker / NAME | Correlation To RAPP | 1D Price Change % | ||
|---|---|---|---|---|
| RAPP | 100% | +3.74% | ||
| CGEM - RAPP | 50% Loosely correlated | +8.12% | ||
| LXEO - RAPP | 49% Loosely correlated | +4.55% | ||
| AVTX - RAPP | 45% Loosely correlated | +2.84% | ||
| STOK - RAPP | 45% Loosely correlated | +2.69% | ||
| CLDX - RAPP | 44% Loosely correlated | +7.77% | ||
More | ||||
Industry Biotechnology
The Aroon Indicator for RAPP entered a downward trend on October 19, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 62 similar instances where the Aroon Indicator formed such a pattern. In 56 of the 62 cases the stock moved lower. This puts the odds of a downward move at 90%.
The 10-day moving average for RAPP crossed bearishly below the 50-day moving average on September 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 6 of 7 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RAPP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where RAPP's RSI Indicator exited the oversold zone, 3 of 5 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 60%.
The Moving Average Convergence Divergence (MACD) for RAPP just turned positive on October 19, 2026. Looking at past instances where RAPP's MACD turned positive, the stock continued to rise in 25 of 29 cases over the following month. The odds of a continued upward trend are 86%.
RAPP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.332) is normal, around the industry mean (2.978). P/E Ratio (-9.693) is within average values for comparable stocks, (-0.692). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (134.267) among similar stocks. P/S Ratio (92.593) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. RAPP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RAPP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.